Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLFS
stocks logo

BLFS

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
23.71M
-16.3%
--
--
24.53M
-19.76%
--
--
25.59M
+12.66%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by 0.67% over the past three months. During the same period, the stock price has changed by -14.03%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.67%
In Past 3 Month
Stock Price
Go Down
down Image
-14.03%
In Past 3 Month
6 Analyst Rating
up Image0
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 31.33 USD with a low forecast of 30.00 USD and a high forecast of 34.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 20.805
sliders
Low
30.00
Averages
31.33
High
34.00
up Image0
Current: 20.805
sliders
Low
30.00
Averages
31.33
High
34.00
Stephens
Stephens
Overweight
initiated
$30
2025-07-21
Reason
Stephens
Stephens
Price Target
$30
2025-07-21
initiated
Overweight
Reason
Stephens resumed coverage of BioLife Solutions with an Overweight rating and $30 price target and named the stock as the analyst's "Best Idea." BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment "represents a crown jewel asset" as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$27 → $30
2025-03-06
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$27 → $30
2025-03-06
Maintains
Strong Buy
Reason
Northland Capital Markets
Carl Byrnes
Buy
Maintains
$28 → $31
2025-01-08
Reason
Northland Capital Markets
Carl Byrnes
Price Target
$28 → $31
2025-01-08
Maintains
Buy
Reason
Benchmark
Robert Wasserman
Strong Buy
Reiterates
$30
2024-12-19
Reason
Benchmark
Robert Wasserman
Price Target
$30
2024-12-19
Reiterates
Strong Buy
Reason
Keybanc
Paul Knight
Buy
Maintains
$30 → $33
2024-12-13
Reason
Keybanc
Paul Knight
Price Target
$30 → $33
2024-12-13
Maintains
Buy
Reason
KeyBanc raised the firm's price target on BioLife Solutions to $33 from $30 and keeps an Overweight rating on the shares. BioLife, under its new CEO, has completed a quick succession of three asset sales, and the firm's proforma models show a high-growth and high-margin business with its dominance of freeze media for the cell, gene, and CAR-T markets, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$29 → $27
2024-11-18
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$29 → $27
2024-11-18
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLife Solutions Inc (BLFS.O) is -260.06, compared to its 5-year average forward P/E of -1553.78. For a more detailed relative valuation and DCF analysis to assess BioLife Solutions Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1553.78
Current PE
-260.06
Overvalued PE
4248.65
Undervalued PE
-7356.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
91.90
Current EV/EBITDA
41.57
Overvalued EV/EBITDA
204.02
Undervalued EV/EBITDA
-20.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
8.89
Current PS
9.88
Overvalued PS
12.70
Undervalued PS
5.07

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BLFS News & Events

Events Timeline

(ET)
2025-07-28
08:07:03
BioLife Solutions purchases $2M of convertible notes in Pluristyx
select
2025-05-08 (ET)
2025-05-08
16:08:11
BioLife Solutions reports Q1 EPS (1c), consensus (4c)
select
2025-04-07 (ET)
2025-04-07
08:07:06
BioLife Solutions acquires PanTHERA CryoSolutions in cash and stock deal
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-25NASDAQ.COM
Peek Under The Hood: SPSM Has 16% Upside

  • ETF Analyst Target Insights: The SPDR Portfolio S&P 600 Small Cap ETF (SPSM) has an implied analyst target price of $50.54, indicating a potential upside of 15.50% from its current trading price of $43.76.

  • Notable Holdings Performance: Key underlying stocks like Biolife Solutions Inc, Progress Software Corp, and HA Sustainable Infrastructure Capital Inc show significant upside potential, with expected increases of 40.26%, 40.08%, and 37.83% respectively based on analyst targets.

Preview
9.5
07-25PRnewswire
BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025

  • Financial Results Announcement: BioLife Solutions, Inc. will release its second quarter 2025 financial results on August 7, 2025, followed by a conference call and live webcast at 4:30 PM ET to discuss the results and provide a business update.

  • Company Overview: BioLife Solutions specializes in bioproduction products and services for the cell and gene therapy market, focusing on maintaining the health and function of biologic materials throughout their lifecycle.

Preview
8.5
07-04NASDAQ.COM
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts

  • Recent Acquisitions by Ensign Group: The Ensign Group, Inc. has acquired two skilled nursing facilities in Idaho and Texas, expanding its portfolio to 348 healthcare operations across 17 states, with a focus on enhancing patient-centered care and addressing gaps in care availability.

  • Financial Growth and Market Position: The company's acquisitions are expected to boost revenue growth, particularly in its Skilled Services segment, which accounted for 97.5% of total revenues in Q1 2025, while shares have increased by 17.8% over the past year, outperforming industry growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioLife Solutions Inc (BLFS) stock price today?

The current price of BLFS is 20.805 USD — it has decreased -2.14 % in the last trading day.

arrow icon

What is BioLife Solutions Inc (BLFS)'s business?

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

arrow icon

What is the price predicton of BLFS Stock?

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 31.33 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioLife Solutions Inc (BLFS)'s revenue for the last quarter?

BioLife Solutions Inc revenue for the last quarter amounts to 23.94M USD, increased 29.88 % YoY.

arrow icon

What is BioLife Solutions Inc (BLFS)'s earnings per share (EPS) for the last quarter?

BioLife Solutions Inc. EPS for the last quarter amounts to -0.01 USD, decreased -95.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioLife Solutions Inc (BLFS)'s fundamentals?

The market is revising Upward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by 0.67% over the past three months. During the same period, the stock price has changed by -14.03%.
arrow icon

How many employees does BioLife Solutions Inc (BLFS). have?

BioLife Solutions Inc (BLFS) has 159 emplpoyees as of August 03 2025.

arrow icon

What is BioLife Solutions Inc (BLFS) market cap?

Today BLFS has the market capitalization of 995.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free